Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Enlivex Therapeutics Ltd ENLV

Healthcare Biotechnology
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages... see more

Recent & Breaking News (NDAQ:ENLV)

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra(TM) In Patients With Sepsis

GlobeNewswire April 11, 2024

Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Accesswire March 22, 2024

Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis

Accesswire February 26, 2024

Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals

Accesswire February 21, 2024

Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method

GlobeNewswire February 7, 2024

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

GlobeNewswire January 17, 2024

Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis

GlobeNewswire December 20, 2023

MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

GlobeNewswire November 21, 2023

Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results

GlobeNewswire September 11, 2023

Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 7, 2023

Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19

GlobeNewswire August 2, 2023

Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra(TM) In Patients With Sepsis

GlobeNewswire July 31, 2023

Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update

GlobeNewswire June 26, 2023

Enlivex to Present at the 2023 Jefferies Healthcare Conference

GlobeNewswire June 6, 2023

Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy

GlobeNewswire May 31, 2023

Enlivex Announces Issuance of European Patent Covering the Use of Allocetra(TM) to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy

GlobeNewswire May 8, 2023

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra(TM) in Patients Receiving CAR T-Cell Therapy

GlobeNewswire April 19, 2023

Enlivex Appoints Andrew Singer to its Board of Directors

GlobeNewswire April 17, 2023

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials

Accesswire April 14, 2023

Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors

Accesswire April 12, 2023